Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence study of Dapagliflozin 10 mg tablet in healthy Thai volunteers under fasting conditions
TCTR20250608005Phase 1Not yet recruiting
- Sponsor
- Bio-innova
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dapagliflozin (2 arms), sponsored by Bio-innova. Primary endpoint: Primary pharmacokinetic bioequivalence. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
dapagliflozin
Beyond the preview
Go deeper on TCTR20250608005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20250608005.